Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quinfamide
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Quinfamide is a small molecule anti-parasitic drug belonging to the quinoline family, specifically a dichloroacetamide derivative. It acts as a luminal amebicide and antiprotozoal agent, primarily used for the treatment of intestinal amoebiasis and helminthiasis. Its mechanism of action involves interfering with protozoan metabolism, leading to immobilization and death of parasites such as *Entamoeba histolytica*. The drug is administered orally and has been shown to be effective in both acute and chronic intestinal infections[1][3][6][8].
- Brand names
- AmecidAmefinAmenideAmenoxAmenox InfantilAmoebrizAmofarmaBensolminBisidimFarmiverOxalProtosinQuinfateg PlusQuocelSerphamidaVermox PlusZentel Dual
- Other names
- quinfamideQuinfamidumQuinfamidQuinfamida
Beyond the preview
Go deeper on quinfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quinfamide.